Search
Now showing items 1-10 of 52
Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual.
(American Society for Microbiology., 2011-05-12)
The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infection. We
previously identified a Center for AIDS Program of Research in South Africa (CAPRISA) participant, CAP88,
who ...
Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.
(Elsevier., 2012-11-25)
Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically ...
Initial B-Cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
(American Society for Microbiology., 2008)
A window of opportunity for immune responses to extinguish human immunodeficiency virus type 1 (HIV-1) exists from the moment of transmission through establishment of the latent pool of HIV-1-infected cells. A critical ...
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
(Elsevier, 2009-03)
Identifying the earliest neutralizing antibody specificities that are elicited following infection or vaccination
by HIV-1 is an important objective of current HIV/AIDS vaccine research. We have shown previously ...
A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.
(American Society for Microbiology., 2006-05)
In human immunodeficiency virus type 1 (HIV-1) subtype B infections, the emergence of viruses able to use
CXCR4 as a coreceptor is well documented and associated with accelerated CD4 decline and disease progression.
However, ...
The development of CD4 binding site antibodies during HIV-1 infection.
(American Society for Microbiology., 2012-07)
Broadly neutralizing antibodies to the CD4 binding site (CD4bs) of gp120 are generated by some HIV-1-infected individuals, but little is known about the prevalence and evolution of this antibody response during the course ...
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.
(Plos., 2013-10-31)
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine. We previously identified a ...
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate Human Immunodeficiency Virus Type 1 vaccines.
(American Society for Microbiology., 2005-08)
No abstract available.
Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.
(American Society for Microbiology., 2013-02-13)
Broadly cross-neutralizing (BCN) antibodies are likely to be critical for an effective HIV vaccine. However, the ontogeny of such antibodies and their relationship with autologous viral evolution is unclear. Here, we ...
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape.
(Nature Publishing Group., 2012-11)
Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine. Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been unsuccessful, a minority of individuals ...